Lab901 has shipped the first of its next-generation ScreenTape systems for automated RNA QC to Oxford Gene Technology (OGT) in Oxford, UK. ScreenTape R6K is a next-generation platform for RNA QC that automatically delivers the ScreenTape Degradation Value (SDV), an objective quality metric for total RNA samples. Lab901’s ScreenTape platform eliminates steps such as gel reagent preparation, chip priming and chip-vortexing, and avoids all problems associated with cross priming and sample carry-over since individual micro-gels are used for each sample analysis.
“As OGT’s microarray R&D and service business grows, we are continually seeking opportunities to increase throughput whilst maintaining the highest standards of data quality,” commented John Anson, R&D Director at OGT. “Having evaluated Lab901’s ScreenTape platform, we are keen to integrate it into our high throughput microarray facility.” Commenting on the placement, Richard Rowling, Lab901’s Sales and Marketing Director said: “Being the pioneer of microarray-based technologies, we are particularly delighted that OGT has decided to add ScreenTape R6K to their RNA QC workflow.”
Unlike the leading chip-based systems, Lab901’s ScreenTape device can be used more than once. A single sample can be run cost-effectively each time, reserving the rest of the available channels for future experiments. There is no longer any need to batch samples together or throw away unused portions of the consumable, which improves the RNA QC workflow and saves money.
Filed Under: Drug Discovery
